Literature DB >> 33505920

Amplifying Tumor-Stroma Communication: An Emerging Oncogenic Function of Mutant p53.

Valeria Capaci1,2, Fiamma Mantovani1,2, Giannino Del Sal1,2,3.   

Abstract

TP53 mutations are widespread in human cancers. An expanding body of evidence highlights that, in addition to their manifold cell-intrinsic activities boosting tumor progression, missense p53 mutants enhance the ability of tumor cells to communicate amongst themselves and with the tumor stroma, by affecting both the quality and the quantity of the cancer secretome. In this review, we summarize recent literature demonstrating that mutant p53 enhances the production of growth and angiogenic factors, inflammatory cytokines and chemokines, modulates biochemical and biomechanical properties of the extracellular matrix, reprograms the cell trafficking machinery to enhance secretion and promote recycling of membrane proteins, and affects exosome composition. All these activities contribute to the release of a promalignant secretome with both local and systemic effects, that is key to the ability of mutant p53 to fuel tumor growth and enable metastatic competence. A precise knowledge of the molecular mechanisms underlying the interplay between mutant p53 and the microenvironment is expected to unveil non-invasive biomarkers and actionable targets to blunt tumor aggressiveness.
Copyright © 2021 Capaci, Mantovani and Del Sal.

Entities:  

Keywords:  cancer secretome; missense mutant p53; precision therapy; tumor microenvironment; vesicular trafficking

Year:  2021        PMID: 33505920      PMCID: PMC7831039          DOI: 10.3389/fonc.2020.614230

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  89 in total

1.  Retromer disruption promotes amyloidogenic APP processing.

Authors:  Christopher P Sullivan; Anthony G Jay; Edward C Stack; Maria Pakaluk; Erin Wadlinger; Richard E Fine; John M Wells; Peter J Morin
Journal:  Neurobiol Dis       Date:  2011-04-16       Impact factor: 5.996

2.  SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors.

Authors:  Marco Montagner; Elena Enzo; Mattia Forcato; Francesca Zanconato; Anna Parenti; Elena Rampazzo; Giuseppe Basso; Genesio Leo; Antonio Rosato; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nature       Date:  2012-07-19       Impact factor: 49.962

3.  Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.

Authors:  R Shakya; G A Tarulli; L Sheng; N A Lokman; C Ricciardelli; K I Pishas; C I Selinger; M R J Kohonen-Corish; W A Cooper; A G Turner; P M Neilsen; D F Callen
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

4.  An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency.

Authors:  Jennifer J Brady; Chen-Hua Chuang; Peyton G Greenside; Zoë N Rogers; Christopher W Murray; Deborah R Caswell; Ursula Hartmann; Andrew J Connolly; E Alejandro Sweet-Cordero; Anshul Kundaje; Monte M Winslow
Journal:  Cancer Cell       Date:  2016-04-14       Impact factor: 31.743

5.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors:  Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

Review 6.  Pre-metastatic niches: organ-specific homes for metastases.

Authors:  Héctor Peinado; Haiying Zhang; Irina R Matei; Bruno Costa-Silva; Ayuko Hoshino; Goncalo Rodrigues; Bethan Psaila; Rosandra N Kaplan; Jacqueline F Bromberg; Yibin Kang; Mina J Bissell; Thomas R Cox; Amato J Giaccia; Janine T Erler; Sachie Hiratsuka; Cyrus M Ghajar; David Lyden
Journal:  Nat Rev Cancer       Date:  2017-03-17       Impact factor: 60.716

7.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Authors:  Tomer Cooks; Ioannis S Pateras; Ohad Tarcic; Hilla Solomon; Aaron J Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rosenfeld; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C Harris; Varda Rotter; Vassilis G Gorgoulis; Moshe Oren
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

8.  Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5.

Authors:  Fotini Vogiatzi; Dominique T Brandt; Jean Schneikert; Jeannette Fuchs; Katharina Grikscheit; Michael Wanzel; Evangelos Pavlakis; Joël P Charles; Oleg Timofeev; Andrea Nist; Marco Mernberger; Eva J Kantelhardt; Udo Siebolts; Frank Bartel; Ralf Jacob; Ariane Rath; Roland Moll; Robert Grosse; Thorsten Stiewe
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

Review 9.  Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis.

Authors:  Marco Cordani; Raffaella Pacchiana; Giovanna Butera; Gabriella D'Orazi; Aldo Scarpa; Massimo Donadelli
Journal:  Cancer Lett       Date:  2016-04-01       Impact factor: 8.679

Review 10.  p53's Extended Reach: The Mutant p53 Secretome.

Authors:  Evangelos Pavlakis; Thorsten Stiewe
Journal:  Biomolecules       Date:  2020-02-15
View more
  2 in total

Review 1.  A Darwinian perspective on tumor immune evasion.

Authors:  Julieann Puleo; Kornelia Polyak
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-12-18       Impact factor: 10.680

Review 2.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.